The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...